[LINKOR: results of observational program in patients with myocardial infarction]

The results of Assessment Program effective treatment of patients with myocardiaL INfarction drug ProCORalan (ivabradine) in outpatient practice, conducted in 53 cities of the Russian Federation, 333 doctors. Included 1226 patients (822 men and 404 women, average age 60,1+/-9,3 years). Despite treatment, before inclusion in the patients maintained an average 8,17+/-8,60 (mediana 6) angina attacks per week, elevated blood pressure (141,8+/-20,3/86,2+/-11,6 mm Hg) and heart rate (84,5 +/-10,4 beats / min). Adding to ivabradine treatment for 16 weeks resulted in significant (p<0.00001) reduction in heart rate (up to 63,1+/-7,5 beats / min), the number of angina attacks per week (from 8.17 to 1.27) and need for nitroglycerin (from 7.69 to 0.89 tablets per week). Decreased the number of patients that called ambulance assistance (from 35.6 to 1.5%), and hospitalization (from 15.4 to 1.2%). There was a significant (p<0.00001) increase in evaluating the effectiveness of treatment (from 5,4+/-1,8 to 8,9 +/-1,3 points), reducing the risk stratification of patients (6,1+/-1,5 to 4 3+/-2,0 points), increased stability evaluation of state (from 5,6+/-1,9 to 3,7+/-2,2 points) and improved assessment of prognosis (from 5,7+/-2,0 to 3,6 +/-1,9 points). Expressed significantly positive effects observed after 1 month of therapy, after the effect became more pronounced. Significantly improved quality of life estimated by Seattle Angina Questionnaire and Minnesota Living with Heart Failure. The maximum recommended dose ivabradine of 15mg/day were given 50% of the patients, the dose of 10 mg/day - 28%. Adverse effects were reported in 3.3% of patients, of which, according to doctors associated with taking the drug - 0.82%. During follow up, 4 patients died. Thus, the addition of ivabradine to -blocker therapy, persons with a history of myocardial infarction and angina experiencing elevated heart rate, are the tactics of a rational and safe therapy.